• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Nutriband Inc.

    1/23/24 10:53:38 AM ET
    $NTRB
    Industrial Specialties
    Health Care
    Get the next $NTRB alert in real time by email
    SC 13D 1 ea191987-13dtiijet_nutriband.htm SCHEDULE 13D

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    §240.13d-1(a) AND

    AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2(a)

     

    NUTRIBAND INC.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    67092M208

    (CUSIP Number)

     

    Tel: (407) 377-6695

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    December 21, 2023

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 67092M208 Schedule 13D Page 2 of 6 Pages

     

    1   

    NAME OF REPORTING PERSON

     

    T.I.I. - JETSERVICES, LDA

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a): ☐ (b): ☒

    3  

    SEC USE ONLY

     

     

    4  

    SOURCE OF FUNDS

     

    On July 17, 2023, Nutriband Inc. (the “Issuer”) entered into an amended Credit Line Note (the “Note”) Agreement with the Reporting Person, for an increased $5,000,000 credit line facility Note (replacing the $2,000,000 credit line facility with the same lender that the Issuer entered into with the Reporting Person on March 17, 2023). Outstanding advances under the Note bear interest at 7% per annum. The Note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the Note. During the nine months ended October 31, 2023, the Issuer was advanced $2,000,000 on the Note.

     

    On December 21, 2023, the Issuer issued 1,026,720 shares of common stock upon conversion of the $2,000,000 principal and $53,440 accrued interest of the Credit Line Note held by the Reporting Person at a conversion price of $2.00 per share.

     

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Portugal

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    1,347,524*

      8  

    SHARED VOTING POWER

     

    -0-

      9  

    SOLE DISPOSITIVE POWER

     

    1,347,524 *

      10  

    SHARED DISPOSITIVE POWER

     

    -0-

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,347,524*

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    15.92%*

    14  

    TYPE OF REPORTING PERSON

     

    CO (Corporation)

     

    *The calculation is based on 8,459,870 shares of Common Stock outstanding as of December 21, 2023.

     

     

    CUSIP No. 67092M208 Schedule 13D Page 3 of 6 Pages

     

    Item 1. Security and Issuer

     

    This statement on Schedule 13D relates to shares (the “Shares”) of the common stock, par value $0.001 per share (the “common stock”) of Nutriband Inc., a Delaware corporation (the “Issuer”). The principal executive offices of the Issuer are located at 121 South Orange Ave., Orlando, FL 32801. 

     

    Item 2. Identity and Background

     

    (a) This statement on Schedule 13D is being filed by TII Jet Services, LDA, a Portugal limited company (the “Reporting Person”). The Reporting Person is filing this Schedule 13D to report an increase in the number of shares of common stock of the Issuer beneficially owned by the Reporting Person as a result of conversion of a loan made pursuant to the Note held by the Reporting Person into shares of common stock of the Issuer, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on December 29, 2023.

     

    (b) The address of the principal office of the Reporting Person is Rua das Ladieras 5, Porto Santo, Portugal, 9400-131.

     

    (c) The name, residence or business address, present principal occupation or employment and citizenship (or state of organization) of each director, executive officer, trustees, general partner, managing member, control person of the Reporting Persons are listed on Schedule I hereto. The principal business of the Reporting Person is aviation services.

     

    (d) During the last five years, neither the Reporting Person nor any of the persons named in Schedule I has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors).

     

    (e) During the last five years, neither the Reporting Person nor any of the persons named in Schedule I was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding has been or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, U.S. federal or state securities laws or finding any violations with respect to such laws.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    The Reporting Person purchased the 1,026,720 shares of common stock of the Issuer through conversion at the rate of $2.00 per share of the outstanding principal of $2,000,000 and accrued interest of $53,440 at December 21, 2023 on the Note held by the Reporting Person in the ordinary course of its business as a holder of debt of the Issuer (the “Conversion”). The purchase price paid by the Reporting Person for the issued conversion shares was $2.00 per share. 

     

    Item 4. Purpose of Transaction

     

    The Reporting Person expects to review from time to time its investment in the Issuer and may, depending on the market and other conditions: (i) convert future principal amounts added to the Note, (ii) purchase additional shares of common stock or equity security of the Issuer, and (iii) sell all or a portion of the shares of common stock of the Issuer now beneficially owned or related derivatives hereafter acquired by it. Except as set forth in this Item 4, the Reporting Person has no present plans or proposals which relate to or would result in any of the matters set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D.

     

     

    CUSIP No. 67092M208 Schedule 13D Page 4 of 6 Pages

     

    Item 5. Interest in Securities of the Issuer

     

    The percentage of the Issuer’s Common Stock reported owned by the Reporting Person is based on 8,459,720 shares of Common Stock of the Issuer outstanding as of December 21, 2023, and upon 1,026,720 shares issued upon conversion of $2,000,000 of principal and $53,440 of accrued interest on the Note at December 21, 2023 (the “Conversion”), and 320,814 shares of common stock held by Reporting Person at that date. In addition to the shares of common stock acquired in the Conversion described in this Schedule, in October 2021, the Reporting Person converted a note of the Issuer into 17,182 shares of common stock, and over time has purchased 303,632 shares in the open market. 

     

    The information contained in rows 7, 8, 9, 10, 11 and 13 on the cover page of this statement on Schedule 13D is hereby incorporated by reference.

     

    No person other than the Reporting Person is known to have the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    None.

     

    Item 7. Material to Be Filed as Exhibits

     

    Exhibit No.

      Description
       
    1.   Creditline Promissory Note (Amended and Restated as of July 13, 2023)– Incorporated by reference to Exhibit 4.1 to the Issuer’s Current Report on Form 8-K, filed with the SEC on July 14, 2023.
       
    2.   Note Conversion Agreement, dated December 19, 2023 – Incorporated by reference to Exhibit 4.2 to the Issuer’s Current Report on Form 8-K, filed with the SEC on December 29, 2023.

     

     

    CUSIP No. 67092M208 Schedule 13D Page 5 of 6 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement on Schedule 13D is true, complete and correct. 

     

    Dated: January 23, 2024

     

      TII Jet Services, LDA
       
      /s/ Viorica Carlig

      

     

    CUSIP No. 67092M208 Schedule 13D Page 6 of 6 Pages

     

    SCHEDULE I

     

    The name, principal occupation or employment, business address, citizenship (or state of organization) and shares of Common Stock of the Issuer beneficially owned by each manager, executive officer, director or control person of the Reporting Person are set forth below.

     

    Name  Present Principal Occupation or Employment  Business
    Address
      Citizenship  Beneficial
    Ownership
     of Shares
     
    Vitalie Botgros 

    Mr. Botgros is the ultimate beneficial owner of shares of common stock of Issuer owned by the Reporting Person. Mr. Botgros is able to exercise control of the Reporting Person through ownership of 100% of the outstanding shares of Nociata Holding Limited, a Cyprus Limited company, that in turn owns all of the outstanding shares of the Reporting Person.

      (1)  Romania   1,347,524(3)
                   
    Viorica Carlig   President of Reporting Person and President of Nociata Holding Limited. (2)  (1)  Portugal   0 

     

    (1)The business address of these persons is Rua das Ladieras 5, Porto Santo, Portugal 9400-131.

     

    (2)Ms. Carlig disclaims beneficial ownership of these shares of the Issuer’s common stock held by the Reporting Person.

     

    (3)Mr. Botgros is the beneficial owner of 100% of the shares of common stock of the Issuer held by the Reporting Person.

     

     

     

     
    Get the next $NTRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTRB

    DatePrice TargetRatingAnalyst
    1/22/2025$13.00Outperform
    Noble Capital Markets
    More analyst ratings

    $NTRB
    Leadership Updates

    Live Leadership Updates

    See more
    • Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

      The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri

      5/16/24 7:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Financials

    Live finance-specific insights

    See more
    • Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo

      5/10/24 9:00:00 AM ET
      $CANF
      $NTRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Nutriband Inc. Commences Trading on Upstream Under NTRB

      Nutriband among the first issuers to dual list on UpstreamORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".Global investors can now trade by downloading Upstream from their preferred app sto

      1/5/23 6:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Inc. Will Be the First Company to Dual List on Upstream

      Trading scheduled to Commence on Upstream January 5, 2023ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval."We are proud to have a trailblazer like Nutriband as the first company to dual list on Upstream and offer its shares to an international investor-base seeking streamlined access to U.S. companies," says Upstream Co-Founder Mark Elenowitz.The dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, u

      12/30/22 6:30:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NTRB
    SEC Filings

    See more
    • Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference

      ORLANDO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO, Gareth Sheridan will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, June 5th at 4PM Eastern Standard Time. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.  Scheduled 1x1 meetings with the Company are also available for registered, qualified investor attendees. Attendees interested in viewing the live presentation can register for this event, at no cost, here: Virtual Equity Conference Registration A video webcast of the presentation will be available fol

      6/3/25 8:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

      ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the first quarter ended April 30, 2025. Nutriband is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record first quarter reporting revenue of $667,000USD, up 63% % YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS and the increasing Pocono revenue stream is key to the company's focus on shareholder v

      6/2/25 8:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc.

      AUSTIN, Texas, May 27, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Gareth Sheridan, Co-Founder and CEO of Nutriband Inc. (NASDAQ:NTRB), a company engaged in the development of a portfolio of transdermal pharmaceutical products. Duri

      5/27/25 8:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Nutriband Inc.

      10-Q - NutriBand Inc. (0001676047) (Filer)

      5/30/25 4:02:06 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Amendment: SEC Form 10-K/A filed by Nutriband Inc.

      10-K/A - NutriBand Inc. (0001676047) (Filer)

      5/13/25 5:29:18 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 10-K filed by Nutriband Inc.

      10-K - NutriBand Inc. (0001676047) (Filer)

      4/28/25 5:21:20 PM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Goodman Gerald

      4 - NutriBand Inc. (0001676047) (Issuer)

      12/2/24 3:49:25 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by President and Secretary Melnik Serguei

      4 - NutriBand Inc. (0001676047) (Issuer)

      11/29/24 1:58:08 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by CEO Sheridan Gareth

      4 - NutriBand Inc. (0001676047) (Issuer)

      11/29/24 1:11:33 PM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Nutriband with a new price target

      Noble Capital Markets initiated coverage of Nutriband with a rating of Outperform and set a new price target of $13.00

      1/22/25 9:24:55 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Nutriband Inc.

      SC 13D/A - NutriBand Inc. (0001676047) (Subject)

      9/19/24 11:38:15 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Nutriband Inc.

      SC 13G - NutriBand Inc. (0001676047) (Subject)

      2/13/24 8:33:52 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Nutriband Inc.

      SC 13G - NutriBand Inc. (0001676047) (Subject)

      2/12/24 3:57:44 PM ET
      $NTRB
      Industrial Specialties
      Health Care